Search Results

There are 8044 results for: content related to: Synergistic Effects of Irinotecan and Flavonoids on Ehrlich Ascites Tumour-Bearing Mice

  1. You have free access to this content
    Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice

    British Journal of Pharmacology

    Volume 171, Issue 9, May 2014, Pages: 2335–2350, R C P Lima-Júnior, H C Freitas, D V T Wong, C W S Wanderley, L G Nunes, L L Leite, S P Miranda, M H L P Souza, G A C Brito, P J C Magalhães, M M Teixeira, F Q Cunha and R A Ribeiro

    Version of Record online : 11 APR 2014, DOI: 10.1111/bph.12584

  2. You have free access to this content
    Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells

    FEBS Letters

    Volume 581, Issue 8, April 17, 2007, Pages: 1649–1656, Dae Hwa Choi, Jin Sook Ha, Won Hyuck Lee, Jeong Kee Song, Gyu Yeol Kim, Jae Hoo Park, Hee Jeong Cha, Byung Ju Lee and Jeong Woo Park

    Version of Record online : 22 MAR 2007, DOI: 10.1016/j.febslet.2007.02.075

  3. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 3, June 2015, Pages: 219–237, Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Céline Narjoz, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec and Collective work by the Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) and the French Réseau National de Pharmacogénétique Hospitalière (RNPGx)

    Version of Record online : 4 MAY 2015, DOI: 10.1111/fcp.12117

  4. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure

    The Journal of Clinical Pharmacology

    Volume 55, Issue 11, November 2015, Pages: 1303–1312, Alexander K. Berg, Jan C. Buckner, Evanthia Galanis, Kurt A. Jaeckle, Matthew M. Ames and Joel M. Reid

    Version of Record online : 26 JUN 2015, DOI: 10.1002/jcph.543

  5. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice

    Fundamental & Clinical Pharmacology

    Volume 28, Issue 6, December 2014, Pages: 652–660, Céline Chu, Chadi Abbara, Mahamadou Tandia, Mélanie Polrot, Patrick Gonin, Robert Farinotti and Laurence Bonhomme-Faivre

    Version of Record online : 16 APR 2014, DOI: 10.1111/fcp.12071

  6. You have full text access to this OnlineOpen article
    Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo

    Cancer Medicine

    Volume 4, Issue 9, September 2015, Pages: 1309–1321, Joanna P. Wood, Andrew J. O. Smith, Karen J. Bowman, Anne L. Thomas and George D. D. Jones

    Version of Record online : 23 JUN 2015, DOI: 10.1002/cam4.477

  7. You have free access to this content
    Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients


    Volume 118, Issue 12, 15 June 2012, Pages: 3173–3181, C. Daniel Mullins, Fei-Yuan Hsiao, Eberechukwu Onukwugha, Naimish B. Pandya and Nader Hanna

    Version of Record online : 21 OCT 2011, DOI: 10.1002/cncr.26613

  8. You have free access to this content
    Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors


    Volume 115, Issue 1, 1 January 2009, Pages: 207–216, Adam S. Levy, Paul A. Meyers, Leonard H. Wexler, Regina Jakacki, Anne Angiolillo, Sarah N. Ringuette, Marvin B. Cohen, Richard Gorlick and Other site principal investigators: Wayne Furman, MD (St. Jude Children's Research Hospital, Memphis, Tennessee); Rochelle Bagatell, MD (University of Arizona Health Sciences Center, Tucson, Arizona); Lori Luchtman-Jones, MD (Washington University School of Medicine, St. Louis, Missouri); Luis Eduardo Garcia, MD (Hospital CIMA, San Jose, Costa Rica); and Eric Sandler, MD (Nemours Children's Clinic, Jacksonville, Florida).

    Version of Record online : 17 DEC 2008, DOI: 10.1002/cncr.23992

  9. Caspase-mediated pro-apoptotic interaction of panaxadiol and irinotecan in human colorectal cancer cells

    Journal of Pharmacy and Pharmacology

    Volume 64, Issue 5, May 2012, Pages: 727–734, Guang-Jian Du, Chong-Zhi Wang, Zhi-Yu Zhang, Xiao-Dong Wen, Jacqueline Somogyi, Tyler Calway, Tong-Chuan He, Wei Du and Chun-Su Yuan

    Version of Record online : 21 FEB 2012, DOI: 10.1111/j.2042-7158.2012.01463.x

  10. You have free access to this content
    Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapin-Q

    British Journal of Pharmacology

    Volume 163, Issue 5, July 2011, Pages: 1017–1033, Tin T Yow, Elena Pera, Nathan Absalom, Marika Heblinski, Graham AR Johnston, Jane R Hanrahan and Mary Chebib

    Version of Record online : 8 JUN 2011, DOI: 10.1111/j.1476-5381.2011.01315.x

  11. Renal Function as a Predictor of Irinotecan-induced Neutropenia

    Clinical Pharmacology & Therapeutics

    Volume 84, Issue 2, August 2008, Pages: 254–262, FA de Jong, JM van der Bol, RHJ Mathijssen, T van Gelder, EAC Wiemer, A Sparreboom and J Verweij

    Version of Record online : 20 FEB 2008, DOI: 10.1038/sj.clpt.6100513

  12. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors

    Pediatric Blood & Cancer

    Volume 54, Issue 7, 1 July 2010, Pages: 909–915, René Y. McNall-Knapp, Cydni N. Williams, Elaine N. Reeves, Richard L. Heideman and William H. Meyer

    Version of Record online : 14 APR 2010, DOI: 10.1002/pbc.22460

  13. You have free access to this content
    Thromboxane A2, released by the anti- tumour drug irinotecan, is a novel stimulator of Cl secretion in isolated rat colon

    The Journal of Physiology

    Volume 505, Issue 1, November 1997, Pages: 133–144, Hideki Sakai, Takahiro Sato, Noriko Hamada, Miyuki Yasue, Akira Ikari, Bunpei Kakinoki and Noriaki Takeguchi

    Version of Record online : 30 SEP 2004, DOI: 10.1111/j.1469-7793.1997.133bc.x

  14. You have free access to this content
    Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies


    Volume 118, Issue 24, 15 December 2012, Pages: 6144–6151, Razelle Kurzrock, Sanjay Goel, Jennifer Wheler, David Hong, Siqing Fu, Keyvan Rezai, Sonia K. Morgan-Linnell, Saik Urien, Sridhar Mani, Imran Chaudhary, Mohammed H. Ghalib, Aby Buchbinder, François Lokiec and Mary Mulcahy

    Version of Record online : 6 JUN 2012, DOI: 10.1002/cncr.27647

  15. You have free access to this content
    Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells

    British Journal of Pharmacology

    Volume 159, Issue 8, April 2010, Pages: 1693–1703, Wai-Yin Pang, Xin-Lun Wang, Sau-Keng Mok, Wan-Ping Lai, Hung-Kay Chow, Ping-Chung Leung, Xin-Sheng Yao and Man-Sau Wong

    Version of Record online : 23 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00664.x

  16. You have free access to this content
    Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation

    FEBS Letters

    Volume 585, Issue 17, September 02, 2011, Pages: 2755–2762, Estabelle S.M. Ang, Xiaohong Yang, Honghui Chen, Qian Liu, Ming H. Zheng and Jiake Xu

    Version of Record online : 6 AUG 2011, DOI: 10.1016/j.febslet.2011.07.046

  17. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver

    Journal of Pharmaceutical Sciences

    Volume 90, Issue 6, June 2001, Pages: 722–731, Christian Farabos, Marie-Christine Haaz, Pierre Gires and Jacques Robert

    Version of Record online : 8 MAY 2001, DOI: 10.1002/jps.1028

  18. Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients

    Asia-Pacific Journal of Clinical Oncology

    Tetsuji Terazawa, Hitoshi Nishitani, Ken Kato, Hironobu Hashimoto, Kohei Akiyoshi, Yuriko Ito, Akihiro Nakamoto, Satoru Iwasa, Takako Eguchi Nakajima, Tetsuya Hamaguchi, Yasuhide Yamada and Yasuhiro Shimada

    Version of Record online : 6 AUG 2015, DOI: 10.1111/ajco.12405

  19. You have free access to this content
    UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma


    Volume 112, Issue 9, 1 May 2008, Pages: 1932–1940, Chun-Yu Liu, Po-Min Chen, Tzeon-Jye Chiou, Jin-Hwang Liu, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang and Wei-Shu Wang

    Version of Record online : 25 FEB 2008, DOI: 10.1002/cncr.23370

  20. You have free access to this content
    Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan

    British Journal of Pharmacology

    Volume 132, Issue 1, January 2001, Pages: 73–84, Corrado Blandizzi, Barbara De Paolis, Rocchina Colucci, Gloria Lazzeri, Fabio Baschiera and Mario Del Tacca

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0703766